1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Meeting Abstract

    Barker, C. A.; D'Angelo, S. P.; Steckler, A. M.; Lian, M.; Wasilewski, G.; Lacouture, M. E.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL)
    Meeting Abstract

    Locke, F. L.; Lekakis, L. J.; Eradat, H.; Munoz, J.; Tees, M. T.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S.; Popplewell, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting CD47 in lymphoid malignancies with CAR T cells
    Meeting Abstract

    Boardman, A. P.; James, S.; Van Den Brink, M. R. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer
    Meeting Abstract

    Mukherjee, S.; Schroeder, A.; Chatterjee, S.; Cadley, J.; Falcon, C. J.; Mehine, M.; Bandlamudi, C.; Chatterjee, A.; Ladanyi, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Quantifying the growth of clinical actionability in precision oncology using OncoKB
    Meeting Abstract

    Suehnholz, S. P.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Zhang, H.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies
    Meeting Abstract

    Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
    Value in Health (2023)

    Fulltext@MSK | Save
  • Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Westin, J.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save